Copy number variations (CNVs) are key players inducing natural genetic diversity as well as biological dysfunction in humans, often associated with complex diseases such as cancer, obesity, neurodegenerative and autoimmune diseases. The quantitative analyses of CNVs at disease-associated loci, therefore, provide insights into molecular mechanisms of diseases and offers potential for the discovery of novel biomarkers. 

Digital PCR (dPCR) enables accurate detection of copy numbers in the genome, making it an indispensable tool for diagnosis and subsequent analysis of copy number alterations underlying disease progression. 

In this webinar, we will focus on accurate and high-resolution detection of cancer-related CNVs using cell line models and other sample types. We will describe CNV analysis using QIAGEN’s QIAcuity dPCR system, including a quick demo using the QIAcuity dPCR Software Suite. We will provide insights into experimental optimization as well as other aspects of CNV analysis.
About the speaker
Dr. Özlem Karalay, Senior Scientist, Digital PCR Assay Development
Özlem Karalay studied Molecular Biology & Genetics at the Middle East Technical University, Turkey, and obtained her M.Sc. degree in Neuroscience from the MPI for Developmental Biology, Tübingen. She received her doctorate in Neuroscience from the Swiss Federal Institute of Technology (ETH), Zürich. She joined QIAGEN after completion of her postdoctoral research at the MPI for Biology of Ageing, Köln, and since then has been involved in developing the digital PCR assay portfolio, including mutation detection and CNV assays.
Date of recording:Thursday, September 24, 2020
Duration:1 hour
Molecular Biology
Cancer Research
Digital PCR